Hepatitis C Prevalence and Responses to Pegylated Interferon

Ozger H. S., Karasahin O., Toy M. A., Yilmaz S. I., HIZEL K.

VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, vol.23, no.3, pp.71-75, 2017 (ESCI) identifier


Objective: The aim of our study was to identify the hepatitis C prevalence in prisoners and to share experiences of pegylated interferon (peg-IFN) + ribavirin (RBV) treatment.